about
Treatment of gastric cancerEmerging molecular classifications and therapeutic implications for gastric cancerEmerging Role of miRNAs in the Drug Resistance of Gastric CancerTargeted therapy for advanced gastric cancer: A review of current status and future prospectsCompeting endogenous RNA networks and gastric cancerContactin 1: A potential therapeutic target and biomarker in gastric cancerHER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerPhase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case reportDecreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer.MicroRNA-206 suppresses gastric cancer cell growth and metastasis.Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer.Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449aPrognostic significance of ZEB1 and ZEB2 in digestive cancers: a cohort-based analysis and secondary analysis.Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study.Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.Laparoscopic gastrectomy in obese gastric cancer patients: a comparative study with non-obese patients and evaluation of difference in laparoscopic methods.Trends in clinical features, postoperative outcomes, and long-term survival for gastric cancer: a Western experience with 1,278 patients over 30 years.Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1).Capecitabine with radiation is an effective adjuvant therapy in gastric cancers.Treatment strategies in gastric cancer.Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.Microribonucleic acids and gastric cancer.Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer.Affinity peptide developed by phage display selection for targeting gastric cancer.Down-regulation of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human gastric cancer cells.Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer.Pathogenetic mechanisms in gastric cancer.Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study.Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.Clinical and prognostic association of transcription factor SOX4 in gastric cancer.84-year-old man with respiratory distress and abdominal distention.Association of polymorphisms and haplotype in the region of TRIT1, MYCL1 and MFSD2A with the risk and clinicopathological features of gastric cancer in a southeast Chinese population.Prediction of gastric cancer metastasis through urinary metabolomic investigation using GC/MS.Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysisEphA4 is a prognostic factor in gastric cancer.Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer.Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer.
P2860
Q24602875-E6AFACF3-0931-4E21-8D6C-D796ED851B16Q26745525-D3434346-D75A-4DDD-9639-E518F2199CACQ26752006-05DB6A3F-23F1-4614-9B11-7B4BD8228240Q26774138-BAA91595-0C8E-4E50-AF38-1F07F8A0687FQ26778019-98DC1E21-34AC-40B3-B45B-F894C701BD98Q26781524-0E36E1B6-C707-4329-AF8F-1173C7F1FA37Q30837184-E1B1A49E-F82B-4520-A36D-1FAF093E08DAQ33407676-64256ED0-403A-4DE1-A64F-AD42D37B54D9Q33416606-336CFA89-D360-45DC-956F-21C9107C6FE7Q33618023-C9FE176F-B9EA-42CC-85DD-B83FAC47C6EEQ33648209-C0C51C2E-5CAD-448C-BF45-669EBFFF754BQ33676514-3CAD20BB-C043-45AE-8704-0B0E1516E48BQ33688606-49891D0C-A0BB-42B9-B6C7-EDFB4BACCDBEQ33761782-7E402B71-1C4F-4AED-A78D-08C7FA6C8036Q33763860-EC8FF911-BFF3-49F4-99C6-461F48AAA086Q33778285-CA44D976-F6F9-44C2-B1E2-740DE1D9FD15Q33779701-883964CB-B807-4530-B650-4F89C75E4758Q33815386-0D787F7E-7131-4E55-90B8-05EDB84BEDC8Q33965000-E463A451-458A-41E8-8462-4BFC3CC391F9Q34037992-4B9A66C5-82F9-4DBC-B948-BC37BA46C118Q34041435-B282E1EF-7586-4C50-BEE2-AB41F80D17E3Q34082714-55A85033-5CD5-4949-B01D-888AA299A3EDQ34162284-BD77BB10-535B-43DE-8B36-D6F4F2B77B2DQ34240588-1449C33B-4BC6-4BDB-953D-105CA09A6755Q34255463-F660FD60-7F7A-47CD-8AC2-7952CA3CABA0Q34259540-E7EAE608-671D-49EA-ABF5-AF3C549B8760Q34277738-515375E0-96BE-41DC-8B3B-2003B1F6E04AQ34310313-B52692B7-F2BA-4C64-BE9A-9145729C7D19Q34326627-108943FC-5FAD-4F84-B8A2-844BABBA966FQ34416979-971607D4-C9FA-41EA-AD44-2B1E50D4A770Q34450648-456F617C-1549-48C2-BEC2-FCAA784D5422Q34534615-045FD540-9E12-4C40-A22B-1B0470AE89AEQ34541900-E86CE7A0-316C-4AE1-94D8-79B5B854F62CQ34561740-9A78C44B-8365-40BD-B01D-645DDB32255EQ34591157-416EC1B6-99B6-4C68-8DE1-EF324DE572A3Q34672942-1E182B48-CD18-4160-A7AE-6F312BE2EB8DQ34759687-29E29C49-6DCB-4CA6-892F-B5718B4EE7F4Q34786508-8DDF49CD-4BD6-421C-A252-EC86FE1524BFQ34927102-E62C5966-2DC4-4BAF-8268-9702BEB6BE29Q34981334-00A2DD0D-8C38-4B6C-A86B-B032CEF4AB9E
P2860
description
scientific article published on 20 February 2009
@en
наукова стаття, опублікована в серпні 2009
@uk
name
Gastric cancer
@en
type
label
Gastric cancer
@en
prefLabel
Gastric cancer
@en
P2093
P50
P1476
Gastric cancer
@en
P2093
Eric Van Cutsem
Giordano D Beretta
Vincenzo Catalano
P304
P356
10.1016/J.CRITREVONC.2009.01.004
P577
2009-02-20T00:00:00Z